Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 8,261 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Risk Clear all
Terminated Phase 3 Interventional Results available

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

NCT05386550
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Xevinapant, IMRT, Placebo
Drug · Radiation
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Birmingham, Alabama • Tucson, Arizona • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 1 Interventional

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

NCT00588991
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Chronic Myeloid Leukemia, Philadelphia Chromosome Negative, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome, Essential Thrombocythemia, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Polycythemia Vera, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 31, 2026, 5:09 AM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

NCT07656727
View directory record Official record
Conditions
Obesity and Cardiovascular Risk
Interventions
Oral BGE-102, Oral Placebo Matching BGE-102
Drug
Lead sponsor
BioAge Labs, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
16
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Post-Operative Nausea And Vomiting Study In Female Patients

NCT00274690
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Nausea and Vomiting, Postoperative
Interventions
GW679769
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
11
States / cities
San Francisco, California • Melbourne, Florida • West Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 31, 2026, 5:09 AM EDT
Completed No phase listed Observational

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

NCT02743910
View directory record Official record
Conditions
Breast Cancer
Interventions
ptDNA, Tissue sample
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Can Food Timing Reduce Your Diabetes Risk?

NCT05862818
View directory record Official record
Conditions
Dietary Habits
Interventions
Day shift protocol - Diet order A-B, Day shift protocol - Diet order B-A, Night shift protocol - Diet order A-B, Night shift protocol - Diet order B-A
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT01243190
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ofatumumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Factorial Optimization Trial to Test Effects of Coping Intervention Components

NCT05822687
View directory record Official record
Conditions
Anxiety, Depression, Coping Skills, Emotional Problem
Interventions
Education, Reappraisal Coping, Distraction Coping, Relaxation Coping
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
9 Years to 12 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Care4U: Self Management Intervention for Older Adult Caregivers

NCT01764399
View directory record Official record
Conditions
Cardiovascular Risk Factor
Interventions
Care4U
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
65 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Community Health Worker Care Transitions Study

NCT03085264
View directory record Official record
Conditions
Hospitalism
Interventions
Community Health Worker
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 109 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 31, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

NCT07037004
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Biospecimen Collection, Clostridium butyricum CBM588 Strain, Computed Tomography, Pembrolizumab
Procedure · Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Duarte, California • Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer

NCT00033904
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
autologous human tumor-derived HSPPC-96
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
39
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stroke Prevention in the Wisconsin Native American Population

NCT04382963
View directory record Official record
Conditions
Stroke, Atherosclerosis
Interventions
High Risk - intensive coaching, High Risk - standard care, Low Risk - control
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
55 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Madison, Wisconsin • Oneida, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 31, 2026, 5:09 AM EDT
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
567
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The weWomen and ourCircle Intervention for Immigrant, Refugee and Indigenous Women

NCT03265847
View directory record Official record
Conditions
Violence, Domestic, Violence-Related Symptom
Interventions
Culturally-tailored Safety Planning
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
688 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Beef in an Optimal Lean Diet (BOLD) Effects on Metabolic Syndrome

NCT00937638
View directory record Official record
Conditions
Metabolic Syndrome, Cardiovascular Disease
Interventions
BOLD Diet, BOLD-X Diet, Modified DASH Diet
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
30 Years to 60 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 31, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

Effect of NMES on Balance and Fall Risk in Chronic Stroke

NCT04957355
View directory record Official record
Conditions
Chronic Stroke
Interventions
Neuromuscular electrical stimulation (NMES) or Functional electrical stimulation (FES)
Device
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Completed No phase listed Observational

Exogenous Sex Hormones and PONV

NCT06816355
View directory record Official record
Conditions
Postoperative Nausea and Vomiting, Sex Hormone, Transgender
Interventions
Orchiectomy, Hysterectomy, Augmentation mammoplasty
Procedure
Lead sponsor
Riverside University Health System Medical Center
Other
Eligibility
18 Years and older
Enrollment
7,348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Moreno Valley, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 31, 2026, 5:09 AM EDT
Recruiting Phase 4 Interventional

Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score

NCT07490067
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
Metoprolol Succinate, Beta-Blocker Polygenic Score, Illumina Infinium Global Diversity Array with Enhanced Pharmacogenomics (PGx)
Drug · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Not yet recruiting Not applicable Interventional

Enhancing an Existing Prevention Strategy to Reduce Intentional Firearm Injuries Among High-risk Youth (Phase 1)

NCT07305467
View directory record Official record
Conditions
Prevention
Interventions
Establish an advisory board of high-risk youth, Feedback and advice sessions, Youth advisory board training, Semi-structured focus groups
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
13 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Recruiting Phase 2 Interventional

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

NCT05208307
View directory record Official record
Conditions
Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Dexamethasone, Pomalidomide
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 1 Interventional Results available

Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (Closed to Accrual 4-22-2011)

NCT00866307
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Prophylactic Cranial Irradiation, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
25
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 31, 2026, 5:09 AM EDT
Completed Phase 4 Interventional Results available

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

NCT00117507
View directory record Official record
Conditions
Myelodysplastic Syndromes, Iron Overload
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Stanford, California • Detroit, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Oct 31, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury

NCT04875052
View directory record Official record
Conditions
Osteoarthritis, Knee, Anterior Cruciate Ligament Injuries, Post-traumatic Osteoarthritis, Quadriceps Muscle Atrophy
Interventions
Experimental: Whole Body Vibration, Experimental: Local Muscle Vibration, Standard ACL Rehabilitation
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 35 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 31, 2026, 5:09 AM EDT